Brian Buntz
Popularized by the Russian economist Nikolai Kondratiev, long wave theory holds that decades of economic progress follow from technological breakthroughs such as was the case with the development of the steam engine, the railway, electrical and chemical engineering, automobiles, and computing technology.
In the most recent period, the microprocessor is the single most important technology, making possible everything from personal computers and smartphones, to smart bionic limbs and wireless-enabled medical devices. Indeed, much of our very culture now seems to revolve around the microprocessor.
Perhaps another technology will emerge as a key driver of medical technology in years to come. And medicine could be one of the principal industries to benefit from the next decades-long technological period, which we could be on the cusp of entering now. The Slovak theorist Daniel Smihula refers to the next decades-long phase as the post-informational technological revolution, and expects it to begin between 2015 and 2020.
A 2010 Allianz report also forecasted a wave of medical technology innovation playing a central role in the next long-term technological phase, arguing that such periods typically emerge after major financial crashes or periods of economic stagnation, and that the Great Recession may be one such example of that. Kondratiev himself believed in a long-term boom–bust cycle, asserting that the Great Depression would not spell the end of capitalism but give rise to a new period of economic success in the West. Stalin apparently disagreed and had the theorist shot by a firing squad.
Whether long-wave theorists are right about the early 21stcentury giving rise to another technological megacycle, there is a definite need for a new wave of innovation in healthcare—in part because the world’s graying population. By 2050, the population percentage in the United States that is over 65 stands to roughly double—and nearly triple in Asia and Latin America. Add to that growing pressures to contain healthcare costs and an uptick in chronic diseases, and we’ve got a big problem on your hands.
If Kondratiev’s grand vision is true, there is a good chance that much of the prognosticating about the future of medical technology will seem myopic by comparison. For one thing, a lot of projections about healthcare’s future are based on applications of electronics. And while electronics will undoubtedly play an integral in an ever-widening number of medical technologies, long-wave theory holds that one technology revolution lays the groundwork for the next. So it is possible that the innovation made possible by electronics could give rise to other technological fields that would characterize the next era. Contenders could include fields like nanotechnology, genomics, biotechnology, or 3-D printing, any of which may ultimately catalyze a wave of long-term medical innovation.
Such a shift may be already underway. The Economist just penned an article stating that the U.S. healthcare system is a “wasteful and inefficient industry, is in the throes of great disruption.” Similar upheaval can be seen elsewhere.
Perhaps revolution is a good word to describe the next period of technological evolution in medicine. While there is clearly a need for novel devices that make healthcare more precise and efficient, any new technology that threatens entrenched medical business models must battle against those who would preserve the status quo.
Economist article below:
THE best-known objective of America’s Affordable Care Act of 2010—commonly known as Obamacare—was to ensure that the 40m-plus Americans who lacked health insurance could get it. Less widely appreciated, but at least as important, are the incentives and penalties the law introduced to make the country’s hideously expensive and poorly performing health services safer and more efficient. Economists are debating how much credit Obamacare should get for a recent moderation in the growth of health costs, and for a fall in the number of patients having to be readmitted to hospital (see article). Whatever the answer, many companies see the disruption unleashed by the reforms as the business opportunity of a lifetime.
One of the biggest shifts under way is to phase out the “fee for service” model, in which hospitals and doctors’ surgeries are reimbursed for each test or treatment with no regard for the outcome, encouraging them to put patients through unnecessary and expensive procedures. Since Obamacare they are increasingly being paid by results—a flat fee for each successful hip replacement, say. There are also incentives for providers which meet cost or performance targets, and new requirements for hospitals to disclose their prices, which can vary drastically for no clear reason
Millions of people are now looking for health insurance on the new public exchanges set up under the reforms. And Obamacare has come into effect at a time when American employers, who often provide health cover for their workers, are seeking to cut its cost by encouraging them to shop around on private exchanges, and by offering less generous plans.
The upshot is that there are growing numbers of consumers seeking better treatment for less money. Existing health-care providers will have to adapt, or lose business. All sorts of other businesses, old and new, are seeking either to take market share from the conventional providers, or to provide the software and other tools that help hospitals, doctors, insurers and patients make the most of this new world.
Patients are increasingly having to pay higher “deductibles” out of their own pockets, before the insurance kicks in, to keep the cost of the cover down. So for minor ailments and simple tests, it makes sense for such patients to go to one of the increasing numbers of walk-in clinics, staffed by well-qualified nurses, on the premises of retail pharmacies such as CVS and Walgreens (see chart). The prices are clear, the care is cheap and the service is quick. Walgreens has a partnership with Theranos, a diagnostics firm, which offers customers a range of tests from a tiny drop of blood. Walmart, a giant supermarket chain with many in-store pharmacies, also intends to become one of the leading sellers of affordable health services, says Alex Hurd, its product-development chief.
For injuries and illnesses that are more serious but not immediately life-threatening, lots of “urgent-care centres” are being opened as an alternative to going to a hospital emergency unit. Private-equity firms are pouring money into independent chains of centres. Merchant Medicine, a consulting firm, reckons that between them, these chains now have just over 1,500 urgent-care centres, up from about 1,300 at the start of 2013. The market is still fragmented but a national brand could emerge from one of the largest chains, such as Concentra or MedExpress.
Some hospital operators, seeking to cut their costs of care, and choosing to be among the disrupters rather than the disrupted, are also opening urgent-care centres. Aurora Health Care, a Wisconsin-based chain of hospitals and clinics, now has more than 30 of them.
Hospital operators are now facing a classic “innovator’s dilemma”, as described by Clay Christensen, a Harvard business professor. If they persist with their high-cost business model even as their customers discover that cheaper alternatives are good enough, they will be in trouble. According to Strata Decision Technology, an analytics firm, many hospital groups saw what was coming and started to cut their costs well before the provisions of Obamacare started to bite. One of the fastest movers is Advocate Health Care, a hospital operator from Illinois, which says it now earns two-thirds of its revenues from value-based payments.
The largest chains of for-profit hospitals, such as Tenet Healthcare, HCA and Community Health Systems, are rather profitable. They have trimmed their costs, been conservative with capital and, thanks to Obamacare raising the number of Americans with health insurance, now have more patients and fewer bad debts. However, credit-rating agencies are worried about the prospects for the not-for-profit hospitals, which are 60% of the total. With lower margins, and less capital to make investments, they have become targets for takeover, says Jim Bonnette of The Advisory Board Company, another consulting outfit.
As a result further consolidation in the hospital business is likely. This could mean greater efficiency and lower costs. But if antitrust authorities are not vigilant, it may lead in the longer term to a concentration of market power. If so, the benefits from the efficiencies being wrung out of the hospital system may end up in the pockets of shareholders rather than saving patients and insurers money.
Obamacare is also encouraging the creation of all sorts of health-related advisory and intermediary companies that help care providers, insurers and patients save money. A company called Vitals approaches employees on behalf of their company’s health plan, and offers them cash rewards, and a taxi, if they agree to be treated at a cheaper provider. The sums to be saved can be astonishing: a new cost-comparison tool created by Blue Cross Blue Shield, a big alliance of private health insurers, has found that a colonoscopy with a biopsy costs $8,489 at one clinic in Chapel Hill, North Carolina, but just $928 at another provider in Greensboro, only 50 miles (80km) or so away.
Cohealo offers a “sharing economy” solution for hospitals and clinics wanting to make the best use of expensive equipment, in much the same way as Airbnb helps people with spare rooms fill them with paying guests. Doximity is trying to be a Facebook for doctors, letting them refer patients and discuss treatments securely without the blizzard of faxes they rely on today. Grand Rounds is a sort of medical Match.com: an online matchmaker that pairs patients with specialists. As in other industries, administrators are being tempted to switch to renting software and data storage in the online “cloud”: Athenahealth, a seller of medical back-office software, is trying to get doctors and hospitals to move patients’ health records onto its cloud-based service.
Preliminary diagnosis
For supporters of Obamacare, it is clear that the reforms are empowering patients, driving public and private health insurers to achieve better value, forcing existing providers to shape up and providing opportunities for disruptive newcomers. Digital technology is also helping to increase transparency about prices, making it easier to share information and increase efficiency. For some analysts it all adds up to a “new health economy”—as PwC, a consulting firm, puts it—the most significant re-engineering of the American health system, by far the world’s costliest, since employers began providing cover for their workers in the 1930s.
And the revolution has only just begun. The Obama administration recently set a target of making 50% of Medicare payments value-based, rather than fee for service, by the end of 2018. America’s largest private payers have a target of 75% by 2020. So hospitals do not have long to shape up. Some will have their profits squeezed, and customers stolen by new rivals. Some may close, or be taken over. But for other businesses, from supermarket and pharmacy chains to digital-health startups, there will be billions to be made.